Bluereg is an expanding regulatory affairs consultancy serving the pharmaceutical industry for more than 10 years.
With offices in the US (Boston, San Francisco) and Europe (Paris, Nice, London, Zurich, and Amsterdam), BlueReg is supporting biopharma and pharma industry innovative companies looking to develop, register, and launch their medicinal products in the European market.
In recent years, Bluereg has worked and specialized its service offering for a lot of biotech/biopharmaceutical companies developing life-transforming treatments (cell therapies, gene therapies, tissue engineering).
More specifically, BlueReg has created an affiliate called “PharmaBlue” able to offer a one-stop-shop solution for companies looking to take advantage of early access programs in France.
Indeed, the French early access program is a fantastic opportunity, allowing companies developing products for rare diseases, or diseases with no existing treatments, to reach patients sometimes even before FDA (Food and Drug Administration) approval in the US.
PharmaBlue is also proposing a solution for companies looking to have a ready-to-go regulatory set-up to commercialize their products on the french market once they have Marketing Authorization.
Bluereg is now a trusted regulatory partner not to be missed with more than 250+ clients worldwide, of which, the most promising NASDAQ listed companies as well as pharmaceutical industry big players.
With an average growth of 20% per year for 10 years, BlueReg is an expanding company and has now more than 70 consultants who are coming from the pharmaceutical industry.
Learn more about BlueReg: https://blue-reg.com/
Media Contact
Company Name: BlueReg Group
Contact Person: Nicolas Schmitz
Email: Send Email
Country: France
Website: https://blue-reg.com/